Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
February 13, 2015 6:46 AM ESTPiper Jaffray upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to Overweight with a price target of $13.00 (from $7.00), suggesting 100% upside from current levels.
Analyst Charles Duncan commented, "Cytokinetics reported 4Q/FY14 results yesterday, ending '14 with $83M in cash which combined with inflows already in '15... More
Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
February 12, 2015 4:13 PM ESTCytokinetics (NASDAQ: CYTK) reported Q4 EPS of $0.23, $0.40 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $10.8 million.
Financial Guidance
Cytokinetics also announced its financial guidance for 2015. The company anticipates cash... More
